About Ariad Pharmaceuticals
Ariad Pharmaceuticals is a company based in Cambridge (United States) founded in 1991 was acquired by Takeda in January 2017. Ariad Pharmaceuticals has raised $46 million across 7 funding rounds from investors including Credit Suisse and Takeda Pharmaceuticals. The company has 328 employees as of December 31, 2015. Ariad Pharmaceuticals operates in a competitive market with competitors including Adicet Bio, ImmunoACT, Orca Bio, Ossium Health and Nordic Nanovector, among others.
- Headquarter Cambridge, United States
- Employees 328 as on 31 Dec, 2015
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
$118.8 M (USD)13as on Dec 31, 2015
-
Net Profit
-$231.16 M (USD)-42as on Dec 31, 2015
-
EBITDA
-$217.28 M (USD)-36as on Dec 31, 2015
-
Total Equity Funding
$46 M (USD)
in 7 rounds
-
Latest Funding Round
$200 M (USD), Post-IPO
Jun 12, 2014
-
Investors
Credit Suisse
& 1 more
-
Employee Count
328
as on Dec 31, 2015
-
Acquired by
Takeda
(Jan 09, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Ariad Pharmaceuticals
Ariad Pharmaceuticals has successfully raised a total of $46M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in June 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ariad Pharmaceuticals
Ariad Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Credit Suisse and Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Wealth management, asset management, and investment banking services are offered.
|
Locked | Locked | Locked | |
|
Takeda Pharmaceuticals is engaged in developing innovative medicines globally.
|
Locked | Locked | Locked |
Investor details for Ariad Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ariad Pharmaceuticals
Investment portfolio details for Ariad Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ariad Pharmaceuticals
Detailed financials for Ariad Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ariad Pharmaceuticals Comparisons
Peer comparison for Ariad Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ariad Pharmaceuticals
Ariad Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adicet Bio, ImmunoACT, Orca Bio, Ossium Health and Nordic Nanovector, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Immune cell therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cell therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| Locked | Locked | Locked |
Ossium Health is focused on bioengineering for improved health.
|
|
| Locked | Locked | Locked |
Antibody radionuclide conjugates are developed for haematological cancers.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer and genetic diseases are developed.
|
Detailed competitors of Ariad Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ariad Pharmaceuticals
Complete news archive for Ariad Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ariad Pharmaceuticals
Ariad Pharmaceuticals was founded in 1991 and raised its 1st funding round 1 year after it was founded.
Ariad Pharmaceuticals is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Ariad Pharmaceuticals is a funded company, having raised a total of $46M across 7 funding rounds to date.
As of Dec 31, 2015, the latest employee count at Ariad Pharmaceuticals is 328.
Annual revenue of Ariad Pharmaceuticals is $118.8M as on Dec 31, 2015.
Ariad Pharmaceuticals is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. Its product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), A32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph ALL). Also investigating Iclusig for the treatment of other cancer such as lung, biliary. Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK) to treat non-small cell lung cancer (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR) and it is developing it to treat non-small cell lung cancer.
Ariad Pharmaceuticals's top competitors include Orca Bio, Ossium Health and Adicet Bio.
Ariad Pharmaceuticals has 2 investors. Key investors include Credit Suisse, and Takeda Pharmaceuticals.